Wednesday, November 10, 2010

AstraZeneca CEO Worries That FED Budget Cuts May Hurt Pharma's Bottom Line

Reuters has;

David Brennan, CEO of AZ says that proposed reductions in Federal Spending following the massive shift in Which Party is now running the US House - could lop up to 20% out of the FDA's budget, ..... and That, could slow up FDA reviews of new products and cost the drug companies Big Money.

And FDA approval/expanded approval of those 'Life Saving' drugs like AstraZeneca's Seroquel needs to be speeded up, Why?

We love it when Congress talks budget cuts, but that talk has to be followed through on. Call their Offices and tell them Why you voted for a sea change.

No comments: